Due to their side effect/adverse reaction profile unspecific MAO-Is have limited use in the treatment of depression in PD (Teychenne et al. 1975), while selective, reversible MAO-A inhibitors are recommended (Riederer and Laux 2011), The selective, irreversible MAO-B inhibitors selegiline and rasagiline are used to treat akinesia and motor fluctuations as is with the selective, reversible MAO-B inhibitor safinamide. This evidence concerns the gene MAOB and depressive symptom measurement.